ChemCon GmbH
About us
ChemCon is a contract development and manufacturing partner for APIs and fine chemicals specialized in transferring R&D projects into fully cGMP-compliant manufacturing processes. Customers worldwide use our services to source APIs for clinical trials and/or commercial applications (i.e. orphan diseases), excipients, reference standards, and all kinds of other high-quality specialty chemicals. Our FDA-inspected facilities are optimized for the production of small to medium quantities. With multidisciplinary expertise we can meet your individual demands for small-molecule organic APIs, inorganic compounds including trace elements, polymers, and highly potent or controlled substances – all in full cGMP quality up to injection grade. Comprehensive in-house analytics, stability studies, documentation, and regulatory support complete our services. ChemCon can look back on an outstanding inspection history both by the FDA and European health authorities.Address
Engesserstr 4b
79108 Freiburg i.Br.
Germany
E-mail: marketing@chemcon.com
Phone: +49 761 55970
Internet: www.chemcon.com
Contact person:
Products & Services
ChemCon is a contract development and manufacturing partner for APIs and fine chemicals specialized in transferring R&D projects into fully cGMP-compliant manufacturing processes. Customers worldwide use our services to source APIs for clinical trials and/or commercial applications (i.e. orphan diseases), excipients, reference standards, and all kinds of other high-quality specialty chemicals. Our FDA-inspected facilities are optimized for the production of small to medium quantities. With multidisciplinary expertise we can meet your individual demands for small-molecule organic APIs, inorganic compounds including trace elements, polymers, and highly potent or controlled substances – all in full cGMP quality up to injection grade. Comprehensive in-house analytics, stability studies, documentation, and regulatory support complete our services. ChemCon can look back on an outstanding inspection history both by the FDA and European health authorities.